Evidence map›Paper›PMID 40916393›Full record

ReviewFuture oncology (London, England)2025

How I treat Ph+ acute lymphoblastic leukemia.

Melanie Castro-Mollo, Daniel J DeAngelo, Marlise R Luskin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Melanie Castro-MolloDivision of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6623-6436
Daniel J DeAngeloDivision of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7865-2306
Marlise R LuskinDivision of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5781-4529

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsAntibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDrug Resistance, NeoplasmFusion Proteins, bcr-ablHematopoietic Stem Cell TransplantationHumansImmunotherapyPhiladelphia ChromosomeTreatment OutcomeAntibodies, BispecificFusion Proteins, bcr-ablProtein Kinase Inhibitorschemotherapyclinical trialsHematologic/leukemianovel therapytransplantation

Identifiers

PMID40916393
PMCPMC12520080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.